Endpoints Media Bias

AI Generated News Bias (?): This news source generally presents a neutral and objective view of developments in the biopharma industry, without showing any specific bias towards a particular political or ideological stance [Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints][Endpoints].


AI Bias: ai language models may have limitations in detecting nuanced biases and accurately assessing the ideological stance of text.


May 20, 2023


Show Historical Bias



    





Customize Your AI News Feed







Endpoints Social Media Impact (?): 7



Endpoints Political Bias (?)






Endpoints Most Begging The Question Articles


A sign of what's coming? Presidential hopeful DeSantis targets PBMs and pharma transparency

Private startup claims a PhIIa win in subset of ALS patients, but questions remain

FDA warns Procter & Gamble over NyQuil label's ingredient listings

'Harder to find homes': Latest wave of biotech layoffs could test the ... - Endpoints News




Endpoints Most Opinionated Articles


#trekfortomorrow #3: How to survive the rigors of the Pacific Crest Trail and a career in cancer research

BioXCel touts healthy volunteer data for neuro therapy; Ionis, Chinook partner on rare kidney disease

Peter Hecht has a new syndicate, $81M in backing and a fresh shot at glory as his last start-up sputters out

FDA adcomm votes 11-2 to expand Roche's Polivy label in DLBCL - Endpoints News




Endpoints Most Appeal to Authority Articles


US government to SCOTUS: Take up the Teva-GSK 'skinny' generic drug label case

Jazz loses appeal, will have patent delisted from the Orange Book

BioMarin seeks label expansion for achondroplasia drug; FDA lifts Inhibikase full clinical hold

Merck asks EMA to reevaluate rejected Covid-19 antiviral




Endpoints Most Subjective Articles


Esperion stock halved after Daiichi discord over $440M heart pill milestones

Eisai's Leqembi and Lilly's donanemab could bring in $10B+ in combined sales by 2030

Metaphore Biotechnologies sprouts from Flagship with $50M to mimic nature for new drugs

Merz Aesthetics hands the mic to Christina Aguilera in Botox rival campaign




Endpoints Most Fearful Articles


US government to SCOTUS: Take up the Teva-GSK 'skinny' generic drug label case

Short supply of commonly used cancer drugs raises concerns among hospital pharmacists




Endpoints Most Gossipy Articles


Three's a crowd as another Kite exec hits the exit; Surfing tough waters, Celyad Oncology picks up new CEO

'Harder to find homes': Latest wave of biotech layoffs could test the ... - Endpoints News




Endpoints Most Prescriptive Articles    

One final push: EU pharma industry group demands competition check on incoming legislative overhaul

Congress moves bill requiring declassification of Covid-19 origins info to Biden's desk

Biden budget wants to more than double number of negotiated drugs under Medicare, and eliminate hepatitis C

UK R&D credit increase, faster drug approvals promised in budget speech

Novavax raises warning about ability to stay in business

Bristol Myers axes German launch of new cancer drug, citing pricing hurdles

Survey says drug commercialization should stretch back, incorporate digital insights for doctors

A sign of what's coming? Presidential hopeful DeSantis targets PBMs and pharma transparency




Click points to explore news by date. News sentiment ranges from -10 (very negative) to +10 (very positive) where 0 is neutral.





Endpoints Recent Articles

Most recent